Brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will report $58.03 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with the highest sales estimate coming in at $60.00 million and the lowest estimate coming in at $56.40 million. Vanda Pharmaceuticals reported sales of $49.14 million in the same quarter last year, which would suggest a positive year over year growth rate of 18.1%. The company is scheduled to report its next earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $224.33 million for the current year, with estimates ranging from $220.10 million to $229.00 million. For the next year, analysts expect that the company will post sales of $274.63 million, with estimates ranging from $247.10 million to $326.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The business had revenue of $59.06 million for the quarter, compared to analysts’ expectations of $54.19 million. During the same period in the previous year, the company earned $0.15 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year.
Several research analysts recently weighed in on VNDA shares. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Friday, August 2nd. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Thursday, August 1st. Stifel Nicolaus restated a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st. Oppenheimer set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, May 5th. Finally, ValuEngine upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $26.57.
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total value of $1,117,856.48. Following the transaction, the chief executive officer now directly owns 1,276,343 shares in the company, valued at $19,579,101.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy Williams sold 2,575 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total transaction of $37,826.75. Following the completion of the transaction, the senior vice president now owns 57,425 shares in the company, valued at $843,573.25. The disclosure for this sale can be found here. 8.20% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pearl River Capital LLC raised its position in shares of Vanda Pharmaceuticals by 6,148.0% in the first quarter. Pearl River Capital LLC now owns 6,248 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 6,148 shares during the period. O Shaughnessy Asset Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $117,000. Adams Diversified Equity Fund Inc. bought a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $120,000. Pacer Advisors Inc. bought a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $138,000. Finally, Victory Capital Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $144,000. Hedge funds and other institutional investors own 99.33% of the company’s stock.
Vanda Pharmaceuticals stock traded up $0.28 during midday trading on Tuesday, hitting $15.19. 525,000 shares of the stock were exchanged, compared to its average volume of 893,224. Vanda Pharmaceuticals has a 52-week low of $11.83 and a 52-week high of $33.44. The stock has a market capitalization of $794.31 million, a price-to-earnings ratio of 31.65 and a beta of 0.38. The business’s 50-day moving average price is $13.91 and its 200-day moving average price is $16.65.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Further Reading: Average Daily Trade Volume – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.